Valitor CEO Steven Lo (L) and president and CSO Wesley Jackson

A dozen years in the mak­ing, a UC Berke­ley spin­out nabs funds to take on the eye

Large­ly fund­ed by gov­ern­ment grants for the bet­ter part of its first decade, a UC Berke­ley spin­out has se­cured a new CEO and the funds to take its re­search in­to the clin­ic in ear­ly 2024.

The biotech, named by one of the co-founder’s daugh­ters and orig­i­nal­ly scrapped to­geth­er with NIH funds in the af­ter­math of the 2008-09 fi­nan­cial cri­sis, is al­so on a mis­sion to up­end the treat­ment of wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, or AMD, with an in­jectable drug that it claims could be more durable than the “800-pound go­ril­la” in the room, Genen­tech’s Lu­cen­tis and Re­gen­eron/Bay­er’s Eylea.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA